Oncology Therapeutics Articles & Analysis
10 articles found
This contextual behavior makes CCR1 a prime candidate for therapeutic modulation. Unlike receptors with highly selective ligand pools, CCR1’s redundancy ensures robustness of immune response but complicates therapeutic targeting. ...
Alfa Cytology, which stands at the forefront of oncology service provision in New York United States, has announced its sophisticated antibody-drug conjugates(ADCs) development services for cancer. ...
Alfa Cytology, a developer of oncology innovation, has announced its latest venture small molecule Poly(ADP-ribose) polymerase inhibitor development services. ...
Glycan microarrays allow researchers to detect these changes and correlate them with disease stages or therapeutic responses, providing valuable tools for diagnostics and personalized medicine. 3. ...
Presently, these bio-molecules are at the epicenter of therapeutic advancements, driven by the intricate method of antibody modification and conjugation. It involves the attachment or fusion of antibodies with other bioactive substances to enhance their efficacy in diagnostics and therapeutics. One key advantage that modified and conjugated antibodies have is ...
The contemporary sphere of oncological therapeutics has witnessed a phenomenal shift in methodology, pivoting from conventional treatment modalities to exploring and utilizing the power of biological entities, notably viruses. ...
Snyder to Navigating Cancer’s Board and especially value her point of view as a recognized leader in oncology and therapeutic development,” said Bill Bunker, Navigating Cancer’s CEO. ...
In the developed world, 1 in 4 people die from cancer or cancer-related disease, and cancer accounts for 13% of deaths globally. Oncology is the fastest growing therapeutic area by revenue and number of clinical trials. ...
In the precision medicine era, diagnostics have become integral to the development of novel therapeutics. Oncology has led the way with molecular diagnostics supporting an explosion of investment and innovation in targeted therapeutics. ...
It provides access to a comprehensive collection of well-established tumor models for early-stage oncology research and increases their translational capabilities to the clinic. ...